Valuation : Poxel

Market Cap 12.57M 14.58M 11.83M 10.77M 20.26M 1.38B 20.37M 140M 54.42M 704M 54.72M 53.54M 2.33B P/E 2023
-0.52x
P/E 2024 -0.36x
Enterprise Value 79.65M 92.34M 74.93M 68.26M 128M 8.76B 129M 886M 345M 4.46B 347M 339M 14.78B EV / Sales 2023
33.3x
EV / Sales 2024 11.2x
Free-Float
94.27%
Yield 2023 *
-
Yield 2024 -
1 day-0.20%
1 week-4.64%
Current month-1.79%
1 month-1.55%
3 months-10.88%
6 months-23.64%
Current year-15.64%
1 week 0.2
Extreme 0.195
0.21
1 month 0.19
Extreme 0.1926
0.25
Current year 0.19
Extreme 0.1926
0.48
1 year 0.19
Extreme 0.1926
0.48
3 years 0.12
Extreme 0.115
0.95
5 years 0.12
Extreme 0.115
6.84
10 years 0.12
Extreme 0.115
13.8
Manager TitleAgeSince
Chief Executive Officer 59 10/06/2026
Director of Finance/CFO - 01/12/2022
Corporate Officer/Principal - 01/05/2023
Director TitleAgeSince
Chairman - 31/07/2025
Director/Board Member - 31/07/2025
Director/Board Member - 31/07/2025
Date Insider Type Main position Quantity % Market Cap. Importance
2/4/22 A Exercice

Founder

67,000 0.2334%
2/4/22 A Exercice

Founder

6,666 0.0232%
1/30/21 A Free

Founder

25,263 0.0888%
Change 5-day change 1-year change 3-year change Capi.($)
-0.20%-4.64%-35.28%-66.37% 12.32M
-0.25%-4.10%+38.38%+92.61% 68.21B
+0.72%-0.56%+47.29%+87.96% 64.25B
-0.25%-1.92%-10.72%+436.70% 26.54B
+0.33%-10.61%+1.95%-16.27% 25.61B
+1.21%+0.97%+31.96%-18.14% 19.88B
-6.09%-12.08%+226.11%+375.00% 17.13B
+0.65%-5.40%-1.24%+534.13% 14.93B
+4.12%+0.30%+52.03%+150.18% 14.1B
-0.24%+5.18%+23.04%+190.97% 12.45B
Average -0.01%-4.29%+37.35%+176.68% 26.31B
Weighted average by Cap. +0.05%-3.22%+41.55%+158.39%

Financials

2023 2024
Net sales 1.98M 2.3M 1.86M 1.7M 3.19M 218M 3.21M 22.03M 8.57M 111M 8.62M 8.44M 368M 6.64M 7.69M 6.24M 5.69M 10.69M 730M 10.75M 73.79M 28.72M 371M 28.88M 28.26M 1.23B
Net income -35.09M -40.68M -33.01M -30.07M -56.55M -3.86B -56.85M -390M -152M -1.96B -153M -149M -6.51B -18.3M -21.22M -17.22M -15.69M -29.5M -2.01B -29.66M -204M -79.23M -1.02B -79.67M -77.95M -3.4B
Net Debt 46.42M 53.82M 43.67M 39.78M 74.81M 5.11B 75.22M 516M 201M 2.6B 202M 198M 8.61B 67.08M 77.77M 63.1M 57.49M 108M 7.38B 109M 746M 290M 3.75B 292M 286M 12.45B
Logo Poxel
Poxel is a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare disorders. For the treatment of NASH, PXL065 (deuterium-stabilized R-pioglitazone) met its primary endpoint in a streamlined Phase 2 trial (DESTINY-1). In rare diseases, development of PXL770, a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator, is focused on the treatment of adrenoleukodystrophy (ALD) and autosomal dominant polycystic kidney disease (ADPKD). TWYMEEG® (Imeglimin), Poxel's first-in-class product that targets mitochondrial dysfunction, is marketed for the treatment of type 2 diabetes in Japan by Sumitomo Pharma and Poxel expects to receive royalties and sales-based payments. Poxel has a strategic partnership with Sumitomo Pharma for Imeglimin in Japan.
Employees
5
Date Price Change Volume
02/09/26 0.1974 -0.20% 106,997
01/09/26 €0.1978 -1.59% 188,538
31/08/26 €0.2010 0.00% 442,611
28/08/26 €0.2010 -0.25% 265,811
27/08/26 €0.2015 -2.66% 214,820
  1. Stock Market
  2. Stocks
  3. POXEL Stock